Positive COVID-19 vaccine responses persist in patients with RA receiving rituximab

In patients with rheumatoid arthritis receiving rituximab, a positive humoral response following COVID-19 vaccination persists regardless of continued rituximab infusion, according to data published in Rheumatology.
The researchers added that repeated vaccine doses administered “as late as possible” after the lowest possible rituximab (Rituxan, Genentech) dose appears to be the optimal COVID-19 vaccination strategy for this population.
“Rheumatoid arthritis (RA) patients treated with rituximab (RTX) have both an increased risk of COVID-19 hospitalization and a reduced humoral

In patients with rheumatoid arthritis receiving rituximab, a positive humoral response following COVID-19 vaccination persists regardless of continued rituximab infusion, according to data published in Rheumatology.
The researchers added that repeated vaccine doses administered “as late as possible” after the lowest possible rituximab (Rituxan, Genentech) dose appears to be the optimal COVID-19 vaccination strategy for this population.
“Rheumatoid arthritis (RA) patients treated with rituximab (RTX) have both an increased risk of COVID-19 hospitalization and a reduced humoral